selinexor and Breast-Neoplasms

selinexor has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for selinexor and Breast-Neoplasms

Article	Year
Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer. Molecular and cellular endocrinology, 2022, 04-05, Volume: 545 Histone deacetylase (HDAC) is closely related to the initiation and development of breast cancer (BC). Its inhibitor (HDACi) has been used to treat BC, while the efficacy of clinical trials was not reached expectations. HDACi combined with other drugs may be an effective strategy. This study explored the effect of HDACi tucidinostat combined with selinexor, an exportin 1 (XPO1) inhibitor, on ER Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydrazines; Mice; Mice, Nude; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2022

Article

Year

Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.

Molecular and cellular endocrinology, 2022, 04-05, Volume: 545

Histone deacetylase (HDAC) is closely related to the initiation and development of breast cancer (BC). Its inhibitor (HDACi) has been used to treat BC, while the efficacy of clinical trials was not reached expectations. HDACi combined with other drugs may be an effective strategy. This study explored the effect of HDACi tucidinostat combined with selinexor, an exportin 1 (XPO1) inhibitor, on ER

Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydrazines; Mice; Mice, Nude; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2022